116 related articles for article (PubMed ID: 26766917)
1. High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy.
Wang C; Fu X; Cai X; Wu X; Hu X; Fan M; Xiang J; Zhang Y; Chen H; Jiang G; Zhao K
Onco Targets Ther; 2016; 9():117-22. PubMed ID: 26766917
[TBL] [Abstract][Full Text] [Related]
2. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
[TBL] [Abstract][Full Text] [Related]
3. High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.
Wang CY; Deng JY; Cai XW; Fu XL; Li Y; Zhou XY; Wu XH; Hu XC; Fan M; Xiang JQ; Zhang YW; Chen HQ; Perez R; Jiang GL; Zhao KL
Oncotarget; 2015 Jul; 6(21):18674-82. PubMed ID: 26124180
[TBL] [Abstract][Full Text] [Related]
4. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence.
Subramanian S; Sridharan N; Balasundaram V; Chaudhari S
South Asian J Cancer; 2019; 8(2):112-115. PubMed ID: 31069192
[TBL] [Abstract][Full Text] [Related]
6. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.
Li HM; Li P; Qian YJ; Wu X; Xie L; Wang F; Zhang H; Liu L
BMC Cancer; 2016 Dec; 16(1):946. PubMed ID: 27955638
[TBL] [Abstract][Full Text] [Related]
7. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
[TBL] [Abstract][Full Text] [Related]
8. Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Thai Hoa NT; Quang Huy H
Cureus; 2020 May; 12(5):e8105. PubMed ID: 32426197
[TBL] [Abstract][Full Text] [Related]
9. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
de Castro Junior G; Segalla JG; de Azevedo SJ; Andrade CJ; Grabarz D; de Araújo Lima França B; Del Giglio A; Lazaretti NS; Álvares MN; Pedrini JL; Kussumoto C; de Matos Neto JN; Forones NM; Fernandes Júnior HJ; Borges G; Girotto G; da Silva IDCG; Maluf-Filho F; Skare NG
Eur J Cancer; 2018 Jan; 88():21-30. PubMed ID: 29179134
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
[No Abstract] [Full Text] [Related]
11. The status of perineural invasion predicts the outcomes of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma.
Ning ZH; Zhao W; Li XD; Chen LJ; Xu B; Gu WD; Shao YJ; Xu Y; Huang J; Pei HL; Jiang JT
Int J Clin Exp Pathol; 2015; 8(6):6881-90. PubMed ID: 26261575
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of postoperative radiotherapy for locally advanced esophageal squamous cell carcinoma.
Zhang Z; Xu L; Di X; Zhang C; Ge X; Sun X
Ann Palliat Med; 2019 Nov; 8(5):708-716. PubMed ID: 31865731
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of NS1-BP expression in esophageal squamous cell carcinoma].
Ren K; Qian D; Wang YW; Pang QS; Zhang WC; Yuan ZY; Wang P
Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):21-27. PubMed ID: 29365413
[No Abstract] [Full Text] [Related]
14. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
15. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.
Reddy BK; Lokesh V; Vidyasagar MS; Shenoy K; Babu KG; Shenoy A; Naveen T; Joseph B; Bonanthaya R; Nanjundappa ; Bapsy PP; Loknatha ; Shetty J; Prasad K; Tanvir Pasha CR
Oral Oncol; 2014 May; 50(5):498-505. PubMed ID: 24613543
[TBL] [Abstract][Full Text] [Related]
16. [Phase II clinical trial of h-R3 combined radiotherapy for locoregionally advanced nasopharyngeal carcinoma].
Wu RR; Wu SX; Zhao C; Xie FY; Gao JM; Hu WH; Gao YH; Li FY; Cui TT; Lu TX
Ai Zheng; 2007 Aug; 26(8):874-9. PubMed ID: 17697551
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma.
Chen Y; Wu X; Hao D; Cheng X; Zhang L; Zhang Y; Ke S; Shi W; He C
Oncotarget; 2019 Jun; 10(40):4069-4078. PubMed ID: 31258850
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
19. C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome.
Xu YP; Lin G; Sun XJ; Yan MH; Zhang G; Hu JL; Sun WY; Yu JM
J Cancer; 2016; 7(5):587-94. PubMed ID: 27053957
[TBL] [Abstract][Full Text] [Related]
20. Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma.
Song H; Pan B; Yi J; Chen L
Exp Biol Med (Maywood); 2014 May; 239(5):529-41. PubMed ID: 24625442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
